Endocrine Abstracts

Background: Sunitinib (SUN) is a novel oral multitarget tyrosine-kinase inhibitor (TKI) that has demonstrated its efficacy in the treatment of metastatic renal cell carcinoma (mRCC). The thyroid dysfunction is one of the most common side effects of SUN. The mechanisms inducing thyroid dysfunction are still poorly understood.Aim: Identify the incidence, severity, ultrasonographic changes and pattern of response of thyroid function tests during treatment w...